The announcement, which sent Teva’s stock soaring by 26.4% to $20.88 and Sanofi’s up 6.7% to $48.94, marks a significant milestone in IBD treatment development. Promising trial results drive ...

Teva Pharmaceutical Industries' Q4 2024 results were strong, but 2025 guidance underwhelmed, causing a sharp stock sell-off. Management's cautious 2025 guidance sets a low bar, likely to be ...